Hematología y Hemoterapia

Resultados: 405
Tipo Título / Nombre Autor(es) Año
Long-Term Follow up of Front-Line Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide (HiLO trial) for Treatment-Naïve Chronic Lymphocytic Leukemia Felipe Grajales A, Chavez Julio C, Turba EP, Nodzon L, Pérez Leal F, Sandoval Sus J, et al 2018
Long Term Survival Analysis of Multiple Myeloma Patients Receiving Induction Therapy+ Autologous STEM CELL Trasplantation, Comparing Velcade-Dexametasone to Alkylating Polichemotherapy As Induction Therapy Cáceres S, Cardesa R, Cabrera C, Bañas MH, Ibañez F, Prieto J, et al 2018
Characteristics and Outcome of Early T Cell Precursor ALL (ETP-ALL) Patients Treated with High-Risk Spanish Pethema Protocols Genesca E, Morgades M, Montesinos P, Barba P, Gil C, Guàrdia R, et al 2018
Analysis of three salvage treatment regimens after relapsed/refractory acute myeloi leukemia (AML) (FLAG-Ida, FLAGO-IDA and PLERIFLAG) Bergua J, Martínez Cuadrón D, Boluda B, Martínez P, Rodríguez Veiga R, Esteve J, et al 2018
Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role Rodríguez-Otero P, Mateos MV, Martínez-López J, Martín-Calvo N, Hernández MT, Ocio EM, et al 2018
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, et al 2018
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, et al 2018
Pharmacokinetics, efficacy, and safety of high-purity factor x for the prophylactic treatment of hereditary factor x deficiency Liesner RI, Huang JN, Kavakli K, Austin SK, Payne J, Clark K, et al 2018
Estudio multicéntrico nacional y retrospectivo del empleo de agonistas del receptor de trombopoyetina en pacientes adultos con PTI: estudio Vertex 2.0 Lozano Almela ML, Mingot ME, Perera M, Jarque I, , et al 2018
A subset of AML patients shows different quimiosensitivy ex vivo profiles to anthracyclines and its combination with cytarabine; could precision medicine be the key selection criterion? Martínez Cuadrón D, Ballesteros J, Martínez López J, Hernández P, Primo D, Gorrochategui J, et al 2018